Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Dejgaard, Thomas Fremming, Knop, Filip Krag, Tarnow, Lise, Frandsen, Christian Seerup, Hansen, Tanja Stenbæk, Almdal, Thomas, Holst, Jens Juul, Madsbad, Sten, Andersen, Henrik Ullits
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390685/
https://www.ncbi.nlm.nih.gov/pubmed/25838513
http://dx.doi.org/10.1136/bmjopen-2015-007791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390685/
https://www.ncbi.nlm.nih.gov/pubmed/25838513
http://dx.doi.org/10.1136/bmjopen-2015-007791

Ejemplares similares